

Cholesterol & Cardiovascular Health Protocol

Evidence-based probiotic, supplement, and dietary strategies to lower cholesterol and protect your heart through the gut-heart-microbiome axis.

[LDL Reduction](#) | [TMAO Lowering](#) | [Bile Acid Metabolism](#) | [Heart Health](#)

Based on 16 systematic reviews, meta-analyses, and RCTs | Published March 2026

What This Protocol Addresses

This protocol is designed for anyone looking to improve their cholesterol profile and reduce cardiovascular risk through evidence-based, microbiome-targeted strategies. Whether you have mildly elevated LDL, a family history of heart disease, or are looking for natural approaches to complement your current plan, this guide provides a structured, research-backed path forward.

Who This Is For

Adults with borderline-high or elevated LDL cholesterol (above 130 mg/dL), those seeking natural lipid-lowering strategies, individuals experiencing statin side effects who want complementary approaches, and anyone wanting to reduce cardiovascular risk through gut health optimization. This protocol complements (never replaces) your physician's recommendations.

The Five Gut-to-Heart Pathways

Pathway	Mechanism	Clinical Relevance
TMAO Production	Gut bacteria convert dietary choline/carnitine to TMA, then liver oxidizes to TMAO	Higher TMAO linked to atherosclerosis, platelet activation, and +2.36 mmHg systolic BP
Bile Acid Metabolism	Gut bacteria deconjugate bile acids via BSH enzymes, altering enterohepatic recycling	Increased bile acid excretion forces liver to convert more cholesterol to bile acids
SCFA Production	Fiber fermentation produces butyrate, propionate, acetate	SCFAs lower hepatic cholesterol synthesis, reduce inflammation, improve endothelial function
LPS/Endotoxemia	Gram-negative bacteria release LPS through leaky gut	Triggers systemic inflammation, oxidized LDL formation, and arterial plaque progression
Cholesterol Conversion	Certain gut bacteria (e.g., Eubacterium coprostanoligenes) convert cholesterol to coprostanol	Non-absorbable coprostanol is excreted, reducing circulating cholesterol

What the Research Shows (Martins et al. 2024, 67 studies)

A systematic review of 67 studies found that CVD patients consistently show increased Enterobacteriaceae and Streptococcus (pro-inflammatory), decreased Faecalibacterium (anti-inflammatory butyrate producer), and elevated TMAO levels compared to healthy controls. Hypertensive patients specifically show lower microbial diversity and depleted SCFA-producing bacteria.

TMAO: The Gut-Heart Metabolite

Trimethylamine N-oxide (TMAO) has emerged as one of the most studied gut-derived metabolites in cardiovascular research. Your gut bacteria convert dietary nutrients (choline, carnitine, and betaine, found primarily in red meat, eggs, and certain fish) into trimethylamine (TMA). Your liver then oxidizes TMA into TMAO, which enters the bloodstream and promotes atherosclerosis through multiple mechanisms.

TMAO Effect	Evidence	Clinical Significance
Hypertension	Dose-response relationship in meta-analysis of 18 studies (Farhangi 2021)	+2.36 mmHg systolic BP in highest vs lowest TMAO category
Atherosclerosis	Promotes foam cell formation, cholesterol deposition, platelet activation	Causal relationship supported by Mendelian randomization for BP (Canyelles 2023)
Endothelial dysfunction	Impairs nitric oxide availability and vascular relaxation	Contributes to arterial stiffness and impaired blood flow
HDL reduction	Associated with reduced HDL-C in both healthy and CVD populations	TMAO may impair reverse cholesterol transport

How to Lower TMAO Naturally

1. Reduce red meat intake (primary dietary source of carnitine and choline that feed TMA-producing bacteria).
2. Increase plant-based meals (shifts microbiome away from TMA-producing species).
3. Eat more fiber and polyphenols (promote SCFA producers that compete with TMA producers).
4. Probiotics and prebiotics can shift bacterial composition toward species that do not produce TMA.
5. Interestingly, statins may also lower TMAO (meta-analysis: -1.84 umol/L, $p < 0.001$), suggesting gut-modulating effects.

Probiotics for Cholesterol Lowering

Multiple meta-analyses have confirmed that certain probiotic strains can meaningfully reduce total cholesterol and LDL-C. The effect size is modest compared to statins but clinically relevant, particularly for individuals with mild hypercholesterolemia or as adjunctive therapy.

Meta-Analysis	Trials / N	TC Reduction	LDL-C Reduction	Key Finding
Cho & Kim 2015	30 RCTs / 1,624	-7.8 mg/dL	-7.3 mg/dL	Greater effect with higher baseline TC, longer duration, certain strains
Mo et al. 2019	19 RCTs / 967	-9.7 mg/dL	-6.6 mg/dL	Significant in hypercholesterolemic adults; younger subjects respond better
Sun et al. 2022	21 trials / 1,429	-13.1 mg/dL	-10.1 mg/dL	Non-obese healthy adults with hyperlipidemia
Sun & Buys 2015	15 studies / 788	Significant	Significant	Fermented milk > capsule; multi-strain > single; <i>L. acidophilus</i> best for LDL

Optimal Probiotic Protocol

For maximum cholesterol-lowering benefit, evidence suggests: (1) Use multi-strain formulations rather than single strains. (2) Ensure the formulation contains *L. acidophilus*. (3) Take for at least 8 weeks before expecting results. (4) A dose of 10 billion CFU or higher is associated with greater effects. (5) Fermented dairy delivery (yogurt, kefir) may enhance efficacy compared to capsule form.

Star Strain: *L. reuteri* NCIMB 30242 (BSH-Active)

This bile salt hydrolase (BSH)-active strain represents a targeted approach to probiotic cholesterol lowering. BSH enzymes deconjugate bile salts in the intestine, reducing bile acid reabsorption and forcing the liver to pull cholesterol from the bloodstream to synthesize replacement bile acids.

L. reuteri NCIMB 30242 RCT (Jones et al. 2012, 114 subjects, 6 weeks)

LDL-C: -8.92% reduction vs placebo ($p=0.016$). Total cholesterol: -4.81% ($p=0.031$). Non-HDL-C: -6.01% ($p=0.029$). ApoB-100: significant reduction ($p=0.049$). Mechanism confirmed: BSH activity increased total bile acids by >2-fold within 1 week (Martoni 2015), with bile acid changes inversely correlated with plant sterol absorption, confirming the cholesterol elimination pathway.

Nutraceuticals Ranked: The Network Meta-Analysis

A landmark 2022 network meta-analysis compared 10 different nutraceuticals head-to-head across 131 trials with 13,062 participants. This provides the most comprehensive ranking of natural cholesterol-lowering agents available.

Nutraceutical	LDL-C Reduction	Notes
Bergamot	-46.8 mg/dL (-1.21 mmol/L)	Ranked #1 but small evidence base; needs more research
Red Yeast Rice	-36.4 mg/dL (-0.94 mmol/L)	Ranked #2; contains monacolin K (natural lovastatin)
Berberine	Significant (within range)	Also lowers TG and raises HDL; dual metabolic benefit
Plant Sterols/Stanol	Moderate reduction	FDA-approved health claim; blocks cholesterol absorption
Garlic	Moderate reduction	Allicin and sulfur compounds; modest effect
Green Tea Extract	Small-moderate reduction	EGCG as active compound; antioxidant benefits
Artichoke	Small reduction	Luteolin as active compound
Silymarin	Small reduction	Milk thistle extract; liver-protective
Spirulina	Small reduction	Blue-green algae; phycocyanin active compound
Policosanols	NO effect	Despite marketing claims, no lipid-lowering effect confirmed

Important: Red Yeast Rice Contains Natural Lovastatin

Red yeast rice (RYR) is the most potent natural LDL-lowering agent because it contains monacolin K, which is chemically identical to the prescription statin lovastatin. This means RYR carries the same drug interactions and (rare) myopathy risk as statins. Do NOT combine RYR with prescription statins. If you are on statin therapy, RYR is redundant and potentially dangerous. RYR is best suited for individuals who cannot tolerate statins or prefer a natural alternative. Product quality varies widely; choose third-party tested brands.

Berberine: The Multi-Target Lipid Optimizer

Berberine continues to emerge as one of the most versatile natural compounds for cardiovascular and metabolic health. Unlike RYR (which works like a statin), berberine lowers cholesterol through a different mechanism: upregulating LDL receptors on liver cells and activating AMPK, the master metabolic switch. This makes it safe to combine with statins or RYR for additive benefit.

Berberine Meta-Analysis (Ju et al. 2018, 16 RCTs, 2,147 participants)

Total cholesterol: -0.47 mmol/L (-18.2 mg/dL, $p < 0.00001$). LDL-C: -0.38 mmol/L (-14.7 mg/dL, $p < 0.00001$). Triglycerides: -0.28 mmol/L (-24.8 mg/dL, $p = 0.002$). HDL-C: +0.08 mmol/L (+3.1 mg/dL, $p = 0.001$) when used alone. No significant difference in adverse events vs control (RR 0.64, $p = 0.22$).

Parameter	Berberine Effect	Mechanism
LDL-C	-14.7 mg/dL	Upregulates LDL receptor (LDLR) expression on hepatocytes
Triglycerides	-24.8 mg/dL	Activates AMPK, increases fatty acid oxidation
HDL-C	+3.1 mg/dL	May improve reverse cholesterol transport
Total cholesterol	-18.2 mg/dL	Combined LDLR + AMPK + bile acid modulation
Gut microbiome	Reshapes composition	Increases Akkermansia, Bifidobacterium; reduces LPS-producing bacteria
Blood glucose	-0.86 mmol/L (FPG)	Dual benefit for metabolic syndrome patients (Guo 2021, 46 trials)

Berberine Dosing

Standard dose: 500 mg two to three times daily with meals. Start at 500 mg once daily for the first week to assess tolerance. GI side effects (mild nausea, diarrhea) usually resolve within 1-2 weeks. Can be combined with statins (different mechanism), but consult your physician if on multiple medications. Berberine inhibits CYP3A4 and CYP2D6, which can affect drug metabolism.

Omega-3 Fatty Acids: Cardiovascular Protection

Omega-3 fatty acids (EPA and DHA) are among the most extensively studied supplements for cardiovascular health, with data from over 149,000 participants across 38 randomized controlled trials.

Outcome	Risk Reduction (RR)	p-value	EPA vs EPA+DHA
Cardiovascular mortality	0.93 (0.88-0.98)	p=0.01	EPA: 0.82 vs EPA+DHA: 0.94
Non-fatal MI	0.87 (0.81-0.93)	p=0.0001	EPA: 0.72 vs EPA+DHA: 0.92
CHD events	0.91 (0.87-0.96)	p=0.0002	EPA: 0.73 vs EPA+DHA: 0.94
MACE	0.95 (0.92-0.98)	p=0.002	EPA monotherapy superior
Revascularization	0.91 (0.87-0.95)	p=0.0001	EPA monotherapy superior
Triglyceride reduction	~15% decrease	High certainty	Dose-dependent (Cochrane 2020)

EPA Monotherapy Is Superior

A critical finding from the Khan 2021 meta-analysis: EPA-only supplements consistently outperformed EPA+DHA combinations for every cardiovascular outcome measured. For CV mortality, EPA alone reduced risk by 18% (RR 0.82) vs only 6% for EPA+DHA (RR 0.94). This supports the use of high-dose EPA (like icosapent ethyl/Vascepa) for those at elevated cardiovascular risk. However, EPA monotherapy carries a higher risk of atrial fibrillation (RR 1.35) and bleeding (RR 1.49), so physician monitoring is recommended at high doses.

Omega-3 Dosing Guide

General heart health: 1-2 g combined EPA+DHA daily. Triglyceride lowering: 2-4 g daily (prescription-strength may be needed). Prefer EPA-dominant or EPA-only formulations for maximum cardiovascular benefit. Take with a fat-containing meal for absorption. If on blood thinners, consult your physician before high-dose supplementation.

Fiber, Beta-Glucan, and Plant Sterols

Dietary fiber and plant sterols are among the oldest and most well-validated natural approaches to cholesterol lowering. Both work through gut-based mechanisms and have earned FDA-approved health claims.

Oat Beta-Glucan

Meta-Analysis	Trials / N	LDL-C Reduction	Key Notes
Whitehead 2014	28 RCTs, >=3g/day	-0.25 mmol/L (-9.7 mg/dL)	No effect on HDL or TG; greater effect with higher baseline LDL
Ho et al. 2016	58 trials / 3,974	-0.19 mmol/L (-7.3 mg/dL)	Also reduced ApoB -0.03 g/L; median dose 3.5g/day

How Beta-Glucan Works

Oat beta-glucan is a viscous soluble fiber that forms a gel in the intestine. This gel physically traps bile acids, preventing their reabsorption. The liver must then pull LDL cholesterol from the bloodstream to manufacture replacement bile acids. The FDA has approved the health claim: 3g or more of oat beta-glucan daily may reduce the risk of heart disease. Sources include oatmeal (1 cup cooked = ~1.5g), oat bran (1/3 cup = ~2g), and supplements.

Plant Sterols and Stanols

Plant sterols and stanols are natural compounds structurally similar to cholesterol. They compete with dietary cholesterol for absorption in the intestinal lumen, reducing the amount of cholesterol that enters the bloodstream. A comprehensive evidence review (Schoeneck & Iggman 2021) rated plant sterols/stanols as HIGH evidence for at least MODERATE LDL-C reduction (0.20 to 0.40 mmol/L, or roughly 7.7 to 15.5 mg/dL).

Plant Sterol/Stanol Dosing

Effective dose: 2-3 g/day, taken with meals. Available in fortified margarines, yogurt drinks, and supplements. Best taken in divided doses (e.g., 1g with 2-3 meals). Effects seen within 2-3 weeks. Safe to combine with statins for additive LDL lowering. Do not exceed 3g/day as higher doses do not provide additional benefit.

CoQ10: Heart Muscle Support

Coenzyme Q10 (ubiquinone) plays a unique role in this protocol. Unlike the other supplements discussed, CoQ10 does not directly lower LDL cholesterol. Instead, it supports heart muscle function, may reduce all-cause mortality in heart failure patients, and is particularly important for anyone taking statins.

CoQ10 Finding	Evidence	Source
Mortality in heart failure	RR 0.68 (95% CI: 0.45-1.03)	Claxton et al. 2022 (26 trials, 2,250 pts)
Cost-effectiveness	ICER 3,650 GBP/QALY (highly cost-effective)	NHS Health Technology Assessment
Statin interaction	No evidence of treatment interaction	Meta-regression analysis
Safety	No increase in adverse events	Across all included trials
Statin depletion	Statins block mevalonate pathway, reducing endogenous CoQ10	Shared biosynthesis pathway

CoQ10 Dosing

For statin users: 100-200 mg daily (offsets statin-induced CoQ10 depletion). For heart failure support: 200-300 mg daily in divided doses. Use ubiquinol form for better absorption (especially for those over 40). Take with a fat-containing meal. Benefits may take 4-12 weeks to manifest.

Supporting Supplements

Supplement	Dose	Primary Benefit	Evidence Level
Berberine	500 mg 2-3x/day with meals	LDL -14.7, TG -24.8 mg/dL; LDLR upregulation	Strong (16 RCTs, 2,147 pts)
Omega-3 EPA	2-4 g/day with food	CV mortality -7%, MI -13%; TG ~15% reduction	Very Strong (38 RCTs, 149K pts)
Oat beta-glucan	3+ g/day	LDL -7 to -10 mg/dL; bile acid trapping	Strong (58 trials; FDA claim)
Plant sterols	2-3 g/day with meals	LDL -8 to -16 mg/dL; blocks cholesterol absorption	Strong (FDA claim)
CoQ10	100-300 mg/day	Heart muscle support; offsets statin depletion	Moderate (26 trials)
Probiotics (BSH-active)	10+ billion CFU/day	LDL -7 to -13 mg/dL; bile acid metabolism	Moderate-Strong (30+ RCTs)
Vitamin D3	2,000-4,000 IU/day	Supports vascular function; deficiency linked to CVD risk	Moderate

The Tiered Supplement Stack

Tier 1 (Start Here): Berberine OR Red Yeast Rice (not both with a statin) + Omega-3 EPA + Oat beta-glucan. These three target different mechanisms (LDLR upregulation, CV event reduction, bile acid trapping) for synergistic effect. Tier 2 (Add After 4 Weeks): Plant sterols/stanols + BSH-active probiotic + CoQ10 (especially if on a statin). Tier 3 (Optimize): Vitamin D3 + fermented foods + increased plant diversity for long-term microbiome health.

Phase 1: Lower and Protect (Weeks 1–12)

The first phase focuses on actively lowering LDL cholesterol, reducing TMAO production, and establishing the foundation for long-term cardiovascular protection.

Category	Intervention	Timing / Notes
Lipid lowering	Berberine 500 mg 2-3x/day (OR Red Yeast Rice if not on statin)	With meals; start at 500 mg 1x/day for week 1
Omega-3	EPA-dominant or EPA-only, 2-4 g/day	With fat-containing meal; choose high-EPA formulation
Soluble fiber	Oat beta-glucan 3+ g/day (oatmeal, oat bran, or supplement)	Morning meal; can combine with psyllium for added benefit
Plant sterols	2-3 g/day in fortified foods or supplements	Divided across meals; start in week 3-4
Probiotic	BSH-active strain (<i>L. reuteri</i> NCIMB 30242) or multi-strain with <i>L. acidophilus</i>	Daily; minimum 10 billion CFU; at least 8 weeks
CoQ10	100-200 mg/day (200-300 if on statin)	With fat-containing meal; ubiquinol preferred
Diet	Reduce red meat to 1-2 servings/week; increase plant meals	Lowers TMAO substrate; shifts microbiome toward SCFA producers
Fermented foods	1 serving daily (yogurt, kefir, kimchi, sauerkraut)	Introduces diverse <i>Lactobacillus</i> species

Statin Safety Note

If you are currently taking a prescription statin, do NOT add Red Yeast Rice (which contains the same active ingredient). Berberine is safe to combine with statins as it works through a different mechanism (LDLR upregulation vs HMG-CoA reductase inhibition). Always inform your physician about all supplements you are taking.

Phase 2: Optimize and Sustain (Weeks 13–24+)

Once your cholesterol levels have improved (recheck at 12 weeks), the second phase shifts toward sustaining results, optimizing gut health for long-term cardiovascular protection, and addressing specific risk factor profiles.

Risk Profile	Targeted Addition	Evidence
High triglycerides (>150 mg/dL)	Increase omega-3 to 4g/day; add berberine if not already taking	Omega-3: TG ~15% reduction; Berberine: TG -24.8 mg/dL
Low HDL (<40 mg/dL men, <50 women)	Regular aerobic exercise (30+ min, 5x/week); berberine; niacin only under physician guidance	Exercise is most effective HDL-raiser; berberine: +3.1 mg/dL
Elevated inflammation (hs-CRP >2)	Omega-3 EPA 2–4g; curcumin 500mg-1g; increase fiber to 30+g/day	EPA reduces inflammatory markers; fiber boosts butyrate
Family history of CVD	Full supplement stack (Tiers 1–3); Mediterranean diet pattern; annual lipid panel	Comprehensive approach for genetic predisposition
Statin intolerance	Red Yeast Rice 1,200–2,400 mg/day + CoQ10 200mg + berberine	RYR provides statin-equivalent LDL lowering without prescription
Post-menopausal women	Vitamin D 2,000–4,000 IU; omega-3; consider soy isoflavones	Estrogen loss increases CVD risk; D and omega-3 support vascular function

The Gut-Heart Virtuous Cycle

As your gut microbiome shifts toward higher diversity and more SCFA-producing bacteria, multiple cardiovascular benefits compound: lower TMAO production reduces atherosclerotic risk, increased butyrate strengthens the gut barrier (reducing LPS/inflammation), improved bile acid metabolism enhances cholesterol excretion, and healthier vascular endothelium improves blood pressure. A Mediterranean-style diet rich in fiber, polyphenols, and fermented foods drives this virtuous cycle.

Dietary Strategies for Cholesterol and Heart Health

Strategy	What to Do	Why It Works
Increase soluble fiber	Oats, barley, psyllium, legumes, apples; target 25-35g total fiber/day	Traps bile acids; feeds SCFA producers; FDA-approved LDL-lowering claim
Mediterranean diet pattern	Olive oil, nuts, fish, vegetables, whole grains, legumes, moderate red wine	Increases Faecalibacterium, decreases TC -6.77 mg/dL (Yu 2025)
Reduce red meat	Limit to 1-2 servings/week; replace with plant protein, fish, poultry	Reduces choline/carnitine substrates for TMAO production
Increase plant diversity	30+ different plants per week (vegetables, fruits, nuts, seeds, herbs, spices)	Greater microbial diversity = better SCFA production and lower inflammation
Add polyphenol-rich foods	Berries, dark chocolate, green tea, red grapes, pomegranate	Promotes Ruminococcaceae and Alistipes; antioxidant vascular protection
Fermented foods daily	Yogurt, kefir, sauerkraut, kimchi, miso, tempeh	Introduces beneficial Lactobacillus; fermented dairy may enhance probiotic LDL-lowering
Limit processed foods	Reduce ultra-processed foods, trans fats, excess sugar	Trans fats raise LDL + lower HDL; sugar raises triglycerides; emulsifiers damage gut barrier
Avoid unfiltered coffee	Use paper filter for coffee; avoid French press, espresso as daily habit	Unfiltered coffee contains cafestol, which raises LDL moderately to largely (Schoeneck 2021)

The Nutraceutical Combination Effect (Pirro et al. 2016, 14 trials)

A meta-analysis of a combination supplement (RYR + berberine + CoQ10 + policosanol + astaxanthin + folic acid) showed: TC -26.15 mg/dL, LDL-C -23.85 mg/dL, HDL-C +2.53 mg/dL, TG -13.83 mg/dL, glucose -2.59 mg/dL. This demonstrates that multi-target approaches leveraging different cholesterol-lowering mechanisms can produce additive benefits.

Tracking Your Progress

Metric	When to Test	Target / Goal
Lipid panel (TC, LDL, HDL, TG)	Baseline, 12 weeks, then every 6 months	LDL <130 mg/dL (optimal <100); TG <150; HDL >40 men / >50 women
ApoB	Baseline and 12 weeks	<90 mg/dL (optimal <80); better predictor than LDL alone
hs-CRP	Baseline and 12 weeks	<2.0 mg/L; marker of vascular inflammation
TMAO (if available)	Baseline and 6 months	Decreasing trend; no universal cutoff yet
Blood pressure	Monthly or as directed	<130/80 mmHg
Fasting glucose / HbA1c	Baseline and 12 weeks	FPG <100 mg/dL; HbA1c <5.7%
Body weight / waist circumference	Monthly	Waist <40 inches men / <35 inches women

What to Expect

Weeks 2-4: Soluble fiber and plant sterols begin lowering LDL. Gut microbiome starts shifting. Weeks 4-8: Berberine and probiotic effects accumulate. You may notice digestive improvements. Weeks 8-12: Full lipid panel improvement typically visible. LDL reductions of 15-30% are realistic with comprehensive stack. Omega-3 triglyceride effects are well-established. Months 3-6+: Sustained improvements. TMAO production decreases as microbiome adapts. Long-term cardiovascular risk reduction compounds over years of consistent practice.

Sources

1. Martins D et al. (2024). Unravelling the Gut Microbiome Role in Cardiovascular Disease: A Systematic Review and a Meta-Analysis. *Biomolecules*, 14(6):731. DOI: 10.3390/biom14060731
2. Verhaar BJH et al. (2020). Gut Microbiota in Hypertension and Atherosclerosis: A Review. *Nutrients*, 12(10):2982. DOI: 10.3390/nu12102982
3. Abbasalizad Farhangi M, Vajdi M. (2021). Gut microbiota-associated TMAO and increased cardiometabolic risk in adults. *Nutrition Reviews*, 79(9):1022-1042. DOI: 10.1093/nutrit/nuaa111
4. Canyelles M et al. (2023). Gut Microbiota-Derived TMAO: A Causal Factor Promoting Atherosclerotic Cardiovascular Disease? *Int J Mol Sci*, 24(3):1940. DOI: 10.3390/ijms24031940
5. Jamialahmadi T et al. (2025). The Effects of Statin Therapy on Circulating TMAO Levels. *Curr Med Chem*, 32(12):2368-2375. DOI: 10.2174/0109298673245069231010065055
6. Cho YA, Kim J. (2015). Effect of Probiotics on Blood Lipid Concentrations: A Meta-Analysis of RCTs. *Medicine*, 94(43):e1714. DOI: 10.1097/MD.0000000000001714
7. Mo R et al. (2019). Effect of probiotics on lipid profiles in hypercholesterolaemic adults. *Med Clin (Barc)*, 152(12):473-481. DOI: 10.1016/j.medcli.2018.09.007
8. Sun K et al. (2022). Probiotics and serum lipids in non-obese healthy adults with hyperlipidemia. *Nutr Hosp*, 39(1):157-170. DOI: 10.20960/nh.03688
9. Sun J, Buys N. (2015). Effects of probiotics on lowering lipids and CVD risk factors. *Ann Med*, 47(6):430-40. DOI: 10.3109/07853890.2015.1071872
10. Jones ML et al. (2012). Cholesterol-lowering efficacy of BSH-active *L. reuteri* NCIMB 30242 yoghurt. *Br J Nutr*, 107(10):1505-13. DOI: 10.1017/S0007114511004703
11. Osadnik T et al. (2022). A network meta-analysis on the comparative effect of nutraceuticals on lipid profile in adults. *Pharmacol Res*, 183:106402. DOI: 10.1016/j.phrs.2022.106402
12. Ju J et al. (2018). Efficacy and safety of berberine for dyslipidaemias. *Phytomedicine*, 50:25-34. DOI: 10.1016/j.phymed.2018.09.212
13. Khan SU et al. (2021). Effect of omega-3 fatty acids on cardiovascular outcomes. *EClinicalMedicine*, 38:100997. DOI: 10.1016/j.eclinm.2021.100997
14. Whitehead A et al. (2014). Cholesterol-lowering effects of oat beta-glucan: a meta-analysis. *Am J Clin Nutr*, 100(6):1413-21. DOI: 10.3945/ajcn.114.086108
15. Schoeneck M, Iggman D. (2021). The effects of foods on LDL cholesterol levels. *Nutr Metab Cardiovasc Dis*, 31(5):1325-1338. DOI: 10.1016/j.numecd.2020.12.032
16. Claxton L et al. (2022). CoQ10 to manage chronic heart failure with reduced ejection fraction. *Health Technol Assess*, 26(4):1-128. DOI: 10.3310/KVOU6959

Medical Disclaimer

This protocol is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The information provided is based on published peer-reviewed research and is designed to complement, not replace, the relationship between you and your healthcare provider.

Cardiovascular disease is a serious medical condition. If you have been diagnosed with heart disease, high cholesterol, hypertension, or any cardiovascular condition, work closely with your physician before starting any new supplement regimen. Some supplements in this protocol (particularly berberine and red yeast rice) can interact with prescription medications. Never discontinue prescribed medications without medical supervision.

Individual results may vary. The research cited represents population-level averages from clinical trials and may not predict individual outcomes. Always consult a qualified healthcare professional for personalized medical advice.

Copyright 2026 BiomeGuide.com. All rights reserved.